• Led Discovery Science’s Molecular Biology team of seven scientists, focused on crafting viruses and protein for gene therapy targeting various diseases including lysosomal storage disorders and mitochondrial diseases. • Developed the Amicus STABLE protein engineering platform and used it to create highly active and stable versions of GLA for a next generation therapy.• Supervised the production of viral vectors for research and cell-line development.• Invented a library for improved mitochondrial protein delivery.• Designed and tested novel regulator of gene expression for improved tropism.• Developed protein targeting technology for exosomal delivery of therapeutic proteins. • Created split-fluorescence and luciferase systems for determination of cross-correction.• Created efficient and cost-effective plasmid backbones for different types of expression/secretion screening, protein production, and virus production to support gene therapy projects.• Designed, oversaw the creation, and inventorying of ~4000 unique plasmids for engineering of optimized transgenes and delivery methods for genetic diseases

• Manager of the X-ray crystallographic fragment screening core for the HIV Interaction and Viral Evolution Center; responsible for curating fragment library, accessing crystal qualities, and training students• Produced a series of easy to manipulate mammalian high-yield expression vectors for lentiviral, stable cell-line, and transient systems that we have used for the study of viral polyproteins (including HIV-1 gag-pol) using Cryo-EM (work done in the laboratory of Joseph Marcotrigiano)• Created a split-GFP plasmid library designed to allow for rapid, systematic screening of protein constructs and purification tags for soluble expression and subsequent purification. These were used to create soluble Zika polymerase and HIV-1 gag-pol • Developed a methodology for rapid experimental phasing and hot-spot identification using a promiscuous small molecule fragment• Continued development of influenza endonuclease inhibitors using structure-based drug design• Mentored nine lab members in proper laboratory technique and scientific approach• Produced five publications from this work and three presentations at international meetings

• Conducted small molecule fragment screening against influenza endonuclease and HIV-1 integrase catalytic core domain by X-ray crystallography• Mentored two graduate students and supervised three post-doctoral associates conducting experimental drug design involving molecular biology, X-ray crystallography, and biochemistry

• Engineered influenza endonuclease for high-throughput structure-based drug design using rational construct design (crystals diffracted X-rays after engineering to 1.7 Å)• Developed high-throughput activity assays for HIV-1 reverse transcriptase and influenza endonuclease• Created methodologies for 2D-IR studies of drug interactions with HIV-1 reverse transcriptase in solution and in crystallo.• Mentored four graduate students and supervised three post-doctoral associates in experimental design involving molecular biology, X-ray crystallography, and biochemistry.

• Studied HIV-1 proteins for drug development• Applied small molecule fragment screening by X-ray crystallography to HIV-1 reverse transcriptase (RT). New inhibitors, which bind to novel sites, are being developed based on this research• Devised and implemented high-throughput soaking protocols, crystal handling, harvesting, data collection, fragment fitting in electron density maps and refinement. Used python scripting language to optimize workflow• Studied HIV-1 protease and matrix by crystallographic methods • Applied directed evolution approaches (in vitro compartmentalization) to the problem of drug resistance• Instructed and managed a team of one graduate student and five undergraduates

• Led a team of medicinal chemists, virologists, biochemists, and a molecular modeler to develop multiple new classes of small molecule inhibitors of the endonuclease of the influenza RNA-dependent RNA polymerase • Improved the enzyme inhibition potency of a novel hit compound 1500 fold in 6 months. This improvement enabled the detection of cell-based viral inhibition without cytotoxicity.• Determined potency of compounds in mammalian cell-based assays designed to test anti-influenza activity (work done in the laboratory of Luis Martino-Sobrido)• This work produced four patents and five publications (one currently submitted)

Computational analysis of yeast DNA sequences for taxonomic purposes.